Market Overview:
The global novel drug delivery systems market is expected to grow at a CAGR of 10.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of chronic diseases, rising demand for targeted and personalized therapies, and technological advancements in novel drug delivery systems. Based on type, the global novel drug delivery systems market is segmented into liposomes, PEGylated proteins & polypeptides, polymer nanoparticle, protein-drug conjugates, and others. The liposomes segment is expected to account for the largest share of the global novel drug delivery systems market in 2018. This segment is also projected to grow at a high CAGR during the forecast period owing to its ability to target specific cells and tissues with high accuracy.
Product Definition:
Novel Drug Delivery Systems are systems that are used to deliver drugs to specific parts of the body. This is important because it allows the drugs to be delivered directly to the area where they are needed, which improves their effectiveness.
Liposomes:
Liposomes are small vesicular structures composed of phospholipids and water. They are naturally occurring organelles that play a major role in infection protection, cell signaling, and inflammation resolution. Liposomes also have the ability to interact with drug molecules; thus making them an attractive drug delivery system for the treatment of various diseases.
PEGylated Proteins & Polypeptides:
PEGylated proteins and polypeptides are widely used in drug delivery applications. They have gained significant importance as they enable the targeting of proteins to specific tissues or cells. The most important property associated with PEGylation is that it enables the incorporation of non-covalent functionalities on amino acids, which are not naturally occurring lysine residues, but rather any other residue including tyrosine, serine or threonine.
Application Insights:
The others segment held the largest market share in 2017. This is attributed to the high unmet medical needs and growing geriatric population across the globe. The novel drug delivery systems are being studied as an alternative for vitamin D, lithium, antiretrovirals, hormone replacement therapy among others.
The hospitals & clinics application segment is expected to witness lucrative growth over the forecast period owing to rising demand for NDDs from various end-use industries such as pharmaceuticals and biotechnology among others. The cancer treatment centers are also estimated to exhibit significant gains during this period owing to increasing cases of cancer across all age groups globally which demands a higher number of novel drug delivery systems for effective treatment resulting in increased revenue generation opportunities for key industry players over the forecast period.
Regional Analysis:
North America dominated the global novel drug delivery systems market in 2017 owing to the presence of a large number of biopharmaceutical companies and an increase in R&D investment by these companies. The region is expected to maintain its dominance during the forecast period due to constant technological advancements, high healthcare expenditure, and increasing focus on drug development by major players. Asia Pacific is anticipated to grow at a lucrative rate over the forecast period owing to factors such as economic growth, improvement in healthcare infrastructure & reimbursement policies along with rising awareness about novel therapies among patients.
The key players operating within this industry are Nanovi A/S (Denmark), FzioMed (Italy), LEO Pharma GmbH (Germany), Algotech Ltd. (Israel) and Merck KGaA.(Germany).
Growth Factors:
- Increasing prevalence of chronic diseases: The global prevalence of chronic diseases is increasing at an alarming rate. This is primarily because of the changing lifestyles and dietary habits of people across the world. According to a study by the World Health Organization (WHO), non-communicable diseases are responsible for around 63% of all deaths worldwide. This number is expected to increase to 73% by 2030. This presents a huge opportunity for novel drug delivery systems that can help in delivering drugs more effectively to patients suffering from chronic diseases.
- Growing demand for targeted drug delivery: One of the key advantages offered by novel drug delivery systems is their ability to target specific tissues or organs in the body, thus reducing side effects and improving efficacy. There is growing demand for such targeted drug delivery systems, especially from pharmaceutical companies that are looking to develop new drugs and therapies.
- Advances in nanotechnology: Nanotechnology has been one of the key drivers behind advances in novel drug delivery systems over the past few years. With continued advancements in this field, we can expect even better and more sophisticated nanodevices that can be used for delivering drugs accurately and efficiently into cells or tissues targetted areas within the body .This would further boost growth prospects for this market overthe next few years .
Scope Of The Report
Report Attributes
Report Details
Report Title
Novel Drug Delivery Systems Market Research Report
By Type
Liposomes, PEGylated Proteins & Polypeptides, Polymer Nanoparticle, Protein-drug Conjugates, Others, Novel Drug Delivery System
By Application
Hospitals & Clinic, Cancer Treatment Centers, Others
By Companies
Amgen, Teva, Roche, UCB(Union Chimique Belge), Celgene, Merck, Gilead Sciences, Sanofi, Pfizer, Takeda, Bausch?Lomb, Samyang Biopharmaceuticals, Johnson & Johnson, TOLMAR, Astellas, AMAG Pharmaceuticals, AbbVie, Dr Reddy, AstraZeneca, Aspen, Acrotech Biopharma, TWi Pharmaceuticals, Novel Drug Delivery System
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
243
Number of Tables & Figures
171
Customization Available
Yes, the report can be customized as per your need.
Global Novel Drug Delivery Systems Market Report Segments:
The global Novel Drug Delivery Systems market is segmented on the basis of:
Types
Liposomes, PEGylated Proteins & Polypeptides, Polymer Nanoparticle, Protein-drug Conjugates, Others, Novel Drug Delivery System
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals & Clinic, Cancer Treatment Centers, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Amgen
- Teva
- Roche
- UCB(Union Chimique Belge)
- Celgene
- Merck
- Gilead Sciences
- Sanofi
- Pfizer
- Takeda
- Bausch?Lomb
- Samyang Biopharmaceuticals
- Johnson & Johnson
- TOLMAR
- Astellas
- AMAG Pharmaceuticals
- AbbVie
- Dr Reddy
- AstraZeneca
- Aspen
- Acrotech Biopharma
- TWi Pharmaceuticals
- Novel Drug Delivery System
Highlights of The Novel Drug Delivery Systems Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Liposomes
- PEGylated Proteins & Polypeptides
- Polymer Nanoparticle
- Protein-drug Conjugates
- Others
- Novel Drug Delivery System
- By Application:
- Hospitals & Clinic
- Cancer Treatment Centers
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Novel Drug Delivery Systems Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
A novel drug delivery system is a technology that allows for the safe and effective delivery of drugs to specific locations in the body. Novel drug delivery systems can improve patient safety and efficacy by increasing the speed, accuracy, and efficiency of drug administration.
Some of the major companies in the novel drug delivery systems market are Amgen, Teva, Roche, UCB(Union Chimique Belge), Celgene, Merck, Gilead Sciences, Sanofi, Pfizer, Takeda, Bausch?Lomb, Samyang Biopharmaceuticals, Johnson & Johnson, TOLMAR, Astellas, AMAG Pharmaceuticals, AbbVie, Dr Reddy, AstraZeneca, Aspen, Acrotech Biopharma, TWi Pharmaceuticals, Novel Drug Delivery System.
The novel drug delivery systems market is expected to register a CAGR of 10.8%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Novel Drug Delivery Systems Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Novel Drug Delivery Systems Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Novel Drug Delivery Systems Market - Supply Chain
4.5. Global Novel Drug Delivery Systems Market Forecast
4.5.1. Novel Drug Delivery Systems Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Novel Drug Delivery Systems Market Size (000 Units) and Y-o-Y Growth
4.5.3. Novel Drug Delivery Systems Market Absolute $ Opportunity
5. Global Novel Drug Delivery Systems Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Novel Drug Delivery Systems Market Size and Volume Forecast by Type
5.3.1. Liposomes
5.3.2. PEGylated Proteins & Polypeptides
5.3.3. Polymer Nanoparticle
5.3.4. Protein-drug Conjugates
5.3.5. Others
5.3.6. Novel Drug Delivery System
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Novel Drug Delivery Systems Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Novel Drug Delivery Systems Market Size and Volume Forecast by Application
6.3.1. Hospitals & Clinic
6.3.2. Cancer Treatment Centers
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Novel Drug Delivery Systems Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Novel Drug Delivery Systems Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Novel Drug Delivery Systems Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Novel Drug Delivery Systems Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Novel Drug Delivery Systems Demand Share Forecast, 2019-2026
9. North America Novel Drug Delivery Systems Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Novel Drug Delivery Systems Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Novel Drug Delivery Systems Market Size and Volume Forecast by Application
9.4.1. Hospitals & Clinic
9.4.2. Cancer Treatment Centers
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Novel Drug Delivery Systems Market Size and Volume Forecast by Type
9.7.1. Liposomes
9.7.2. PEGylated Proteins & Polypeptides
9.7.3. Polymer Nanoparticle
9.7.4. Protein-drug Conjugates
9.7.5. Others
9.7.6. Novel Drug Delivery System
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Novel Drug Delivery Systems Demand Share Forecast, 2019-2026
10. Latin America Novel Drug Delivery Systems Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Novel Drug Delivery Systems Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Novel Drug Delivery Systems Market Size and Volume Forecast by Application
10.4.1. Hospitals & Clinic
10.4.2. Cancer Treatment Centers
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Novel Drug Delivery Systems Market Size and Volume Forecast by Type
10.7.1. Liposomes
10.7.2. PEGylated Proteins & Polypeptides
10.7.3. Polymer Nanoparticle
10.7.4. Protein-drug Conjugates
10.7.5. Others
10.7.6. Novel Drug Delivery System
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Novel Drug Delivery Systems Demand Share Forecast, 2019-2026
11. Europe Novel Drug Delivery Systems Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Novel Drug Delivery Systems Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Novel Drug Delivery Systems Market Size and Volume Forecast by Application
11.4.1. Hospitals & Clinic
11.4.2. Cancer Treatment Centers
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Novel Drug Delivery Systems Market Size and Volume Forecast by Type
11.7.1. Liposomes
11.7.2. PEGylated Proteins & Polypeptides
11.7.3. Polymer Nanoparticle
11.7.4. Protein-drug Conjugates
11.7.5. Others
11.7.6. Novel Drug Delivery System
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Novel Drug Delivery Systems Demand Share, 2019-2026
12. Asia Pacific Novel Drug Delivery Systems Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Novel Drug Delivery Systems Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Novel Drug Delivery Systems Market Size and Volume Forecast by Application
12.4.1. Hospitals & Clinic
12.4.2. Cancer Treatment Centers
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Novel Drug Delivery Systems Market Size and Volume Forecast by Type
12.7.1. Liposomes
12.7.2. PEGylated Proteins & Polypeptides
12.7.3. Polymer Nanoparticle
12.7.4. Protein-drug Conjugates
12.7.5. Others
12.7.6. Novel Drug Delivery System
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Novel Drug Delivery Systems Demand Share, 2019-2026
13. Middle East & Africa Novel Drug Delivery Systems Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Novel Drug Delivery Systems Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Novel Drug Delivery Systems Market Size and Volume Forecast by Application
13.4.1. Hospitals & Clinic
13.4.2. Cancer Treatment Centers
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Novel Drug Delivery Systems Market Size and Volume Forecast by Type
13.7.1. Liposomes
13.7.2. PEGylated Proteins & Polypeptides
13.7.3. Polymer Nanoparticle
13.7.4. Protein-drug Conjugates
13.7.5. Others
13.7.6. Novel Drug Delivery System
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Novel Drug Delivery Systems Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Novel Drug Delivery Systems Market: Market Share Analysis
14.2. Novel Drug Delivery Systems Distributors and Customers
14.3. Novel Drug Delivery Systems Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Amgen
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Teva
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Roche
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. UCB(Union Chimique Belge)
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Celgene
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Merck
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Gilead Sciences
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Sanofi
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Pfizer
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Takeda
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Bausch?Lomb
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Samyang Biopharmaceuticals
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Johnson & Johnson
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. TOLMAR
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Astellas
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. AMAG Pharmaceuticals
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. AbbVie
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. Dr Reddy
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. AstraZeneca
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. Aspen
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
